Hematopoietic stem cells (HSCs) resides in the umbilical cord blood. From last two decades these cells are well-known for treating 80+ chronic diseases. Scientists have acknowledged their richest potential and are exploring more through research regarding their conceivable regenerative clinical treatment promises. HSCs can be converted into any other blood type to protect individuals from the exposure of blood related diseases like leukemia, myeloma etc.
On the other hand, cord tissue contains mesencymal stem cells (MSCs). These cells found in the tissue of the cord blood can repair several differentiated types of connective tissue of the bones and muscles. So far, there lacks the treatment through MSCs but the research is developing at a greater pace. Sooner it is expected that these MSCs will be able to treat various chronic ailments like heart disease, lungs, Parkinson’s disease, diabetes type 1 etc.
BY NOW MSCs ARE THE MOST DISCUSSED IN THE FIELD OF REGENERATIVE CLINICAL TRIALS DUE TO THEIR CONCEIVABLE CLINICAL PROSPECTS.
Scientists are exploring new ways to address the global burden disease. Their conceivable potential have paved the ray of hope for the potential patients. Amazingly, both mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) contains immaculate potential of regenerating and repairing organ, muscle, skin, nerve cells and tissue. Their stupendous functions have attracted scientists and clinicians from across the globe. Scientists have not only acknowledged their potential but are also further doing research on their conceivable clinical as well as research prospects. Even policy makers across the world are concerned especially public health specialists to get benefited from their richest potential and to bring advancement in public health policies of each state.
Precisely, mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) for their potential are significantly under consideration by scientists and public health specialists across the globe.